CNS Pharmaceuticals, Inc.
CNSP- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001729427
In the last 90 days, CNS Pharmaceuticals, Inc. insiders filed 1 open-market purchase and 0 sales; 11 institutions reported holding it in 13F filings for Q2 2026, worth $1.34M in total; no superinvestor holds it.
Key figures
- Insider buysLast 90 days, $10.0K in total
- 1
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −1 vs. previous quarter
- 11
- 13F valueReported value at the end of Q2 2026
- $1.34M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding CNSP, Q2 2026
No superinvestor reported holding CNSP at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by CNS Pharmaceuticals, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Aug 18, 2026 (view filing)9:01 AM ET | May 18 | 92 daysLate | Fisher MichalDirector | PPurchase | +2.00K | $5.00 | +$10.0K | New position2.00K after | |
| May 20, 2026 (view filing) | May 18 | 2 days | Charles Faith L.Director | PPurchase | +7.10K | $4.79 | +$34.0K | New position7.10K after | |
| Feb 6, 2024 (view filing)10:28 AM ET | Feb 1 | 5 daysLate | Gumulka JerzyDirector | PPurchase | +33.3K | $0.30 | +$10.0K | +344.6%43.0K after | |
| Feb 6, 2024 (view filing)10:27 AM ET | Feb 1 | 5 daysLate | Evans Carl AnthonyDirector | PPurchase | +33.3K | $0.30 | +$10.0K | +26,666.4%33.5K after | |
| Feb 6, 2024 (view filing)10:27 AM ET | Feb 1 | 5 daysLate | Downs ChristopherChief Financial Officer | PPurchase | +66.7K | $0.30 | +$20.0K | +181.3%103.4K after | |
| Feb 6, 2024 (view filing)10:27 AM ET | Feb 1 | 5 daysLate | Climaco John MChief Executive Officer | PPurchase | +166.7K | $0.30 | +$50.0K | +340.1%215.7K after | |
| Aug 23, 2023 (view filing) | Aug 22 | 1 day | Downs ChristopherChief Financial Officer | PPurchase | +27.0K | $1.27 | +$34.3K | +276.3%36.8K after | |
| Aug 16, 2023 (view filing) | Aug 16 | Same day | Climaco John MChief Executive Officer | PPurchase | +2.75K | $1.80 | +$4.95K | +5.9%49.0K after | |
| Aug 1, 2023 (view filing) | Dec 6, 2022-Mar 28, 2023 | 238 daysLate | Priebe Waldemar10% Owner | SSale | −94.3K | $1.41 | −$133.1K | −37.6%156.8K after | 17 lots10b5-1 |
| Apr 21, 2023 (view filing) | Apr 19 | 2 days | Gumulka JerzyDirector | PPurchase | +2.50K | $1.70 | +$4.25K | +34.9%9.67K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in CNS Pharmaceuticals, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Ikarian Capital, LLC | 135,830 | $649.3K | 0.11% | +90,000+196.4% | Added |
| ADAR1 Capital Management, LLC | 70,000 | $334.6K | 0.02% | +70,000 | New |
| Stonepine Capital Management, LLC | 41,573 | $198.7K | 0.15% | −19,427−31.8% | Reduced |
| Boothbay Fund Management, LLC | 13,524 | $64.6K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 10,226 | $48.9K | 0.00% | +10,226 | New |
| Vanguard Capital Management LLC | 6,993 | $33.4K | 0.00% | +6,993 | New |
| UBS Group AG | 1,461 | $6.98K | 0.00% | +732+100.4% | Added |
| Tower Research Capital LLC (TRC) | 799 | $3.82K | 0.00% | −511−39.0% | Reduced |
| Barclays PLC | 19 | $91 | 0.00% | +19 | New |
| Barrett & Company, Inc. | 8 | $38 | 0.00% | 00.0% | Unchanged |